Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET
Company Participants
Louise Wilkie - Investor Relations
Sandy Macrae - Chief Executive Officer
Nathalie Dubois-Stringfellow - Chief Development Officer
Jason Fontenot - Chief Scientific Officer
Prathyusha Duraibabu - Chief Financial Officer
Bettina Cockroft - Chief Medical Officer
Mark McClung - Chief Operating Officer
Conference Call Participants
Gena Wang - Barclays
Yanan Zhu - Wells Fargo
Ritu Baral - Cowen & Company
Operator
Good day, and thank you for standing by. Welcome to the Sangamo Therapeutics Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that this call is being recorded.
I will now turn it over to Louise Wilkie, Head of Corporate Communications and Investor Relations. Please go ahead.
Louise Wilkie
Good afternoon. I'm Louise Wilke, Sangamo's Vice President of Investor Relations and Corporate Communications. Thank you for joining us on the call today. On this call are several members of Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found on our website, angamo.com, under the Investors & Media section on the Events and Presentations page.
This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to the therapeutic and commercial potential of our product candidates -- the anticipated plans and time lines of Sangamo and our collaborators for initiating and conducting clinical trials, dosing and screening patients and presenting clinical data, advancement of our product candidates, advanced with the preclinical programs to the clinic, our investment focus and the sufficiency of our resources, our 2022 financial guidance, upcoming catalysts and other statements that are not historical facts. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC, specifically in our annual report on Form 10-K for the fiscal year ended December 31, 2021, as supplemented by our quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2022. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information, except as required by law. On this call, we discuss our non-GAAP operating expenses. A reconciliation of this measure to our GAAP right operating expenses can be found in today's press release, which is available on our website.